key: cord-0711050-5ckemxsy authors: Chakraborty, Saborni; Gonzalez, Joseph C.; Sievers, Benjamin L.; Mallajosyula, Vamsee; Dubey, Megha; Cheng, Bowie Yik-Ling; Thi Tran, Kim Quyen; Chakraborty, Srijoni; Cassidy, Arianna; Chen, Steven T.; Sinnott, Aanika; Gelbart, Terri; Golan, Yarden; Prahl, Mary; Singh, Upinder; Kim-Schulze, Seunghee; Sherwood, Robert; Zhang, Sheng; Marron, Thomas U.; Gnjatic, Sacha; Gaw, Stephanie L.; Nadeau, Kari C.; Merad, Miriam; Jagannathan, Prasanna; Tan, Gene S.; Wang, Taia T. title: Divergent early antibody responses define COVID-19 disease trajectories date: 2021-05-25 journal: bioRxiv DOI: 10.1101/2021.05.25.445649 sha: 11b507fd5874a50cad16dc502b742c8cc875135b doc_id: 711050 cord_uid: 5ckemxsy Serologic markers that predict severe COVID-19 disease trajectories could enable early medical interventions and reduce morbidity and mortality. We found that distinct features of IgG Fab and Fc domain structures were present within three days of a positive test that predicted two separate disease trajectories in a prospective cohort of patients with COVID-19. One trajectory was defined by early production of neutralizing antibodies and led to mild disease. A distinct trajectory, characterized by an initial period of mild symptoms followed by rapid progression to more severe outcomes, was predicted by the absence of early neutralizing antibody responses with concomitant production of afucosylated IgGs. Elevated frequencies of monocytes expressing the receptor for afucosylated IgGs, FcγRIIIa (CD16a), were an additional antecedent in patients with the more severe outcomes. In mechanistic studies, afucosylated immune complexes in the lung triggered an inflammatory infiltrate and cytokine production that was dependent on CD16a. Finally, in healthy subjects, mRNA SARS-CoV-2 vaccination elicited neutralizing antibodies that were enriched for Fc fucosylation and sialylation and distinct from both infection-induced trajectories. These data show the importance of combined Fab and Fc domain functions in the antiviral response, define an early antibody signature in people who progressed to more severe COVID-19 outcomes and have implications for novel therapeutic strategies targeting FcγRIIIa pathways. IgG activities in vivo arise from combined actions mediated by the fragment antigen-binding (Fab) and fragment crystallizable (Fc) domains. Fab domains determine binding specificity and the ability of antibodies to block virus attachment to host cells while Fc-Fc gamma receptor (FcγR) interactions trigger a variety of effector cell functions. The structure of anti-viral Fab and Fc domains determines whether opsonized virus particles will be neutralized and how they will be engaged by host cells. COVID-19 is associated with a wide range of clinical outcomes and why most people experience mild or no symptoms while others progress to severe disease or death is not well understood. Further, how the kinetics and quality of the early antibody response impact the trajectory of COVID-19 is not fully known. Understanding the Fab and Fc domain structures that predict different COVID-19 disease trajectories would provide an opportunity for early medical interventions to reduce morbidity and mortality associated with this disease. Post-translational modifications (PTMs) of the Fc are one of the major mechanisms by which Fc structure is regulated. Fc fucosylation and sialylation are tightly regulated PTMs that confer distinct and well-defined activities of IgG1 antibodies by governing their affinity to FcγRs expressed on innate immune cells 1, 2 . Engagement of the FcγRs bearing innate immune cells, in turn, transduces the activities of IgGs into cell-mediated immune responses. Low levels of Fc fucosylation (afucosylation) have been observed in late COVID-19, a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), specifically in hospitalized patients with severe disease 3, 4 . Yet, whether Fc afucosylation is a predictive marker of susceptibility to more severe COVID-19 is unknown. One well characterized phenotype within the spectrum of COVID-19 manifestations is mild symptoms lasting for several days followed by rapid progression to more severe symptoms that may require hospitalization 5, 6 . This group is particularly important to study as they present an opportunity to intervene to prevent morbidity and mortality associated with more severe COVID-19. A role for antibodies in modulating COVID-19 severity has been suggested by several studies. Most studies have focused on the role of the Fab in binding and neutralization. Early administration of passively transferred neutralizing antibodies, for example, can protect from severe disease [7] [8] [9] [10] . In addition, a delayed neutralizing response is associated with mortality in severe COVID-19 11 . The afucosylated IgG antibodies that are enriched in patients with severe later-stage disease may also modulate disease 3, 4 . This Fc modification, when incorporated into SARS-CoV-2 immune complexes, enhances affinity for FcγRIIIa/CD16a and can trigger numerous cellular effector functions, including production of inflammatory cytokines by primary monocytes, such as IL-6 and TNF 3 . Whether afucosylated antibodies in patients with severe COVID-19 are a response to severe infection or are antecedent to disease progression has not been clear. Here, we dissect the evolution of neutralizing and afucosylated antibody forms after SARS-CoV-2 infection. By tracing the early antibody signatures associated with distinct disease outcomes, we have been able to identify that early afucosylated antibodies together with low serum neutralizing activity are, in fact, an early predictor of more severe disease outcomes. We also show that two doses of mRNA vaccination elicit antibodies with protective signatures characterized by high neutralizing titers and elevated sialylation and low afucosylation of anti-S IgG Fc. outpatients. To gain an understanding of the kinetics of neutralizing antibody production in COVID-19 and any patterns of production that may be associated with specific disease trajectories, we studied neutralizing antibodies over time in the longitudinal cohort of 109 COVID-19 outpatients from Stanford Hospital Center. These study participants were enrolled within three days of a positive SARS-CoV-2 PCR test. All subjects were assessed by a physician and had asymptomatic or mild COVID-19 at the time of enrollment. Because subjects in this study were enrolled within 3 days of a first positive SARS-CoV-2 PCR test, samples were drawn at an unusually early stage of disease (the median duration of symptoms prior to enrollment was 3 days; mean was 3.11 days) (Fig. 1A) . Disease resolution occurred in most subjects, though the duration of symptoms was highly variable within the cohort (range 0-50 days). Though all subjects had mild COVID-19 at the time of the first sample draw, 8 subjects had acutely worsening symptoms in the hours or days following enrollment, leading to evaluation in the emergency department; five of these individuals ultimately required hospitalization. We term these individuals "progressors" (Table 1) . Overall, this cohort enabled a granular prospective study of the evolution of the different antibody types early after infection in patients with distinct clinical outcomes. Of note, the original purpose of this prospective study was to assess whether interferon lambda could modulate the course of mild COVID-19; thus, study subjects were randomized to receive pegylated interferon lambda (lambda) or placebo after enrollment 12 . Administration of lambda had no effect on the clinical course of disease 12 and there was no correlation between the generation of neutralizing antibodies after infection and receipt of lambda (Extended Data Fig. 1 ). "Early" (study day 0) antibody responses that were characterized here were from samples obtained before subjects received either lambda or placebo treatment. To define the evolution of the antibody response following exposure to SARS-CoV-2, we performed neutralization assays using a pseudotyped vesicular stomatitis virus system. The fifty percent pseudoviral neutralizing antibody titers (pNT50) and IgG binding antibody titers were calculated at study day 0 (enrollment), day 5, day 28, month 7 and month 10 for all subjects from whom samples were available. Levels of both binding and neutralizing antibodies showed a significant increase over time from day 0 and peaked at the day 28 timepoint (Fig. 1B) . The longitudinal pNT50 for each study subject was evaluated by overall Symptom Day (Fig. 1B) and a majority of subjects were negative for neutralizing antibodies on study day 0 (Fig. 1C ). Once initiated, the antibody response was durable and persisted in most people until 7 months postenrollment, after which there was a general decrease in binding titer and in neutralization by month 10 . A graphical representation of the kinetics of neutralizing antibody titers is shown in Fig 1C. ; this analysis revealed heterogeneity in early neutralizing responses within nonprogressors, while progressors were uniformly negative for early neutralizing antibodies despite having measurable anti-S and, in some, anti-N IgG antibodies (Fig. 1D ). We next asked whether there were any qualitative differences in the Fc structures of the IgGs from progressors prior to actual symptom progression. As we have previously observed elevated anti-SARS-CoV-2 Fc afucosylation at a late time point in disease (hospitalization) 3 and also in this study in an independent cohort of 52 hospitalized patients from Mount Sinai Hospital, we sought to clarify whether this Fc modification might actually define people who were at high risk for disease progression at an early time point after infection. Indeed, progressors were distinguished by elevated afucosylated anti-SARS-CoV-2 IgG1 at study enrollment and prior to worsening of symptoms (Fig. 1E ). The level of Fc afucosylation in progressors was similar to levels observed in the hospitalized patients from Mount Sinai Hospital ( Fig 1E) . Other Fc glycoforms were not distinct between progressors and other outpatients, demonstrating specificity of Fc afucosylation as a predictor of disease trajectory (Extended Data Fig. 2) . Interestingly, the frequency of afucosylated anti-SARS-CoV-2 IgG1 was inversely correlated with pNT50 such that higher afucosylation was not present in people with high early neutralizing antibody responses (Fig. 1F ). We next trained and evaluated a random forest classifier by using early neutralization titers and afucosylation as input features to separate progressors and non-progressors. Individually, both Fc afucosylation and early neutralization titers had modest predictive powers, while combining the two features could separate progressors from non-progressors with high predictive accuracy ( Fig. 1G) . Thus, early production of reactive, afucosylated antibodies and poor serum neutralizing activity predicted progression from mild COVID-19 to more severe outcomes (Table 1) . In addition to afucosylated antibody production, a hallmark of patients with severe COVID-19 is inflammatory myeloid cell infiltration into lungs and excessive inflammatory cytokine production [13] [14] [15] . These cells express the low affinity FcγRs FcγRIIa/CD32a (activating), FcγRIIb/CD32b (inhibitory) and, on some subsets, FcγRIIIa/CD16a (activating). These FcγRs are engaged through avidity-based interactions when immune complexes are formed during infection. Depending on the strength of activating and inhibitory signaling, effector cells respond with a proportional level of inflammatory activity 3 . Thus, we investigated whether there were any distinctions in FcγR expression on myeloid cells in subjects with distinct COVID-19 trajectories. To study this, PBMCs collected at study enrollment were assessed for the frequency of different leukocyte subsets and we further quantified the expression of low affinity FcγRs by those subsets. Notably, we found that at study enrollment, progressors already had an increased frequency of CD16a+ monocytes in the peripheral blood compared to other outpatients ( Fig. 2A) . CD16a expression within the myeloid compartment, as a whole, was elevated in progressors, while other low affinity FcγRs were not distinct between progressors and non-progressors (Fig. 2B) . The normalized co-expression of CD16a, CD32a, and CD32b revealed that myeloid cells from progressors exhibited a significantly heightened activating/inhibitory (A/I) FcγR signaling potential ( Figure 2C ). Significant differences in the distribution of FCGR3A allelic variants (F/F, F/V and V/V) were not observed between non-progressors and progressors (Extended Data Fig. 3 ). Overall, elevated frequencies of CD16a+ monocytes and a higher A/I signaling potential of myeloid cells separated progressors and non-progressors. Thus, elevations in both the ligand (afucosylated antibodies) (Fig. 1E ) and the cognate receptor (CD16a) ( Fig. 2A) were correlates of a progressive COVID-19 trajectory. That progressive COVID-19 was heralded by production of poorly neutralizing, afucosylated IgGs prompted us to study whether afucosylated immune complexes modulate the cellular or cytokine milieu within the lung. In this pursuit, we used an in vivo model to study the response to different human immune complexes in the lung of mice that are fully humanized for FcγRs 16 Early robust neutralizing antibody production in "rapid resolvers". Next, we evaluated whether early production of neutralizing antibodies in non-progressors was associated with any COVID-19 trajectory. To study this, we performed a correlation analysis of neutralizing, binding IgG, or binding IgA titers from days 0, 5 or 28 against the time to resolution or total symptom days. Interestingly, the only correlation with duration of disease was between time to resolution and neutralizing antibody and IgA titers at the earliest time point, study day 0. Higher titers of neutralizing and binding antibodies on study day 0 were associated with rapid resolution of symptoms (in 0-7 days) (Fig.4A , B, C) and were positively correlated with levels of white blood cells (WBCs) and platelets (Extended Data Fig. 4 ). There was no difference in the number of days of symptoms prior to enrollment between the rapid resolvers (0-7 days of symptoms) and others (8+ days of symptoms) (Extended Data Fig. 5 ). Overall, these data showed that, while lack of serum neutralizing antibodies and a presence of reactive, afucosylated IgGs predicted symptom progression in mild COVID-19 ( Fig. 1) , early robust neutralizing antibody production was associated with rapid symptom resolution (Fig. 4) . sialylation and afucosylation, no clear trends were observed (Fig. 5B, C) ; this contrasts with our observations after seasonal influenza virus vaccination, suggesting differences in the response that may be based on antigen experience or different vaccine platforms 20 . Interestingly, consistent with prior observations after seasonal influenza virus vaccination, the fold change in antigenspecific IgG Fc sialylation was a correlate of the quality of the vaccine response, with enhanced sialylation predicting a more robust neutralizing antibody response after vaccination (Fig. 5D) 20 . In Cloning, expression and protein purification. The His6-tagged SARS-CoV-2 RBD and full length SARS-CoV-2 spike protein were purified in house as previously described. 3 Briefly, both the constructs were transiently transfected into Expi293F cells (Thermo Fisher Scientific) and proteins purified from culture supernatants Ni-nitriloacedic acid (NTA) resin (GE HealthCare). ELISA. ELISA was performed following a modified version of a protocol described previously 3 . Briefly, 96 Well Half-Area microplates (Corning (Millipore Sigma)) plates were coated with antigens at 2μg/ml in PBS for 1h at room temperature (RT). Next, the plates were blocked for an hour with 3% non-fat milk in PBS with 0.1% Tween 20 (PBST). All serum samples from patients with COVID-19, and the negative controls were heated at 56°C for 1h, aliquoted and stored at - Fig 8) . Cell-free BAL fluid was stored at 4 o C and processed within 24hr to measure cytokine/chemokine content using a LEGENDplex bead array kit (BioLegend). Characterization of these samples was performed under a protocol approved by the Institutional The data was clustered according to the serum neutralization titer kinetics. The correlation and significance levels between any given pair of variables was computed using the rcorr() function in R 1.2.1335 using the Hmisc package and visualized using the corrplot package. Python version 3.8.5 was used for machine learning. The output class progressor was mapped to 1 and non-progressor was mapped to 0, making it a binary classification problem. For the classification task, Random Forest Classifier was used. The input data was split using 6-fold cross validation in which the classifier was trained on 5 folds of the data and tested on the remaining part of the data. The ROC response for all these different datasets were used for calculating the mean area under curve. All other data were analyzed with GraphPad Prism 9.0 software. Fisher's exact test. The cross-correlation matrix shows the inter-relationship between the antibody neutralization titers in COVID-19 patient samples analyzed longitudinally with multiple immune parameters, disease severity and symptom duration. COVID-19 disease resolved earlier in patients with high neutralization titers at enrollment. Data is shown only for statistically significant (p<0.05) Spearman correlation coefficients after Benjamini-Hochberg correction for multiple comparisons. A multi-level assignment was used for each categorical variable to compute the spearman correlation. The assigned levels are listed here: Response (high = 1, low = 0), disease severity (asymptomatic = 0, moderate = 1, severe = 2), severe (no = 0, yes = 1), asymptomatic (no = 0, yes = 1), sex (female = 0, male = 1), obesity (no = 0, yes = 1), and interferon-lambda treatment (no = 0, yes = 1). The size and color of each circle correspond to the pair-wise correlation coefficient. The duration of symptoms prior to enrolment in study participants who had an early resolution of disease (0-7days) as compared to those who had a longer course of disease (8d+). The p value in (C) was calculated using Mann Whitney unpaired t-test. Functional diversification of IgGs through Fc glycosylation IgG Fc Glycosylation in Human Immunity Proinflammatory IgG Fc structures in patients with severe COVID-19 Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity Risk factors for disease progression in COVID-19 patients Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo Delayed production of neutralizing antibodies correlates with fatal COVID-19 Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial An inflammatory cytokine signature predicts COVID-19 severity and survival Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 The spatial landscape of lung pathology during COVID-19 progression Mouse model recapitulating human Fcgamma receptor structural and functional diversity Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study Neutrophils and COVID-19: Nots, NETs, and knots COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages Sampling the host response to SARS-CoV-2 in hospitals under siege IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity Competing Interests: None Correspondence and requests for materials should be addressed to T.T.W All raw data are available in the manuscript or from the corresponding author on request. through SARS-CoV-2 pseudovirus neutralization assays. The first immunization was delivered at day 0 for both vaccine cohorts . The second immunization was delivered at day 28 for the Moderna vaccine cohort and at day 21 for the Pfizer vaccine Gating strategy for immune cell infiltrates in mouse BAL. Neutrophils were defined as viable Ly6G+ CD11b+ CD3-B220-leukocytes. Monocytes were defined as viable CD11b+Ly6G-MERTK-MHC IA/IE-CD3-B220-leukocytes.